Head-to-head evidence
Elranatamab vs GR1803
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
Elranatamab
Marketed by Pfizer
NCT05014412 · Phase 2 · completed
The study was nonrandomized, open-label, and single-arm, with all 85 treated participants receiving elranatamab and no placebo or active comparator. Its primary endpoint was a clinical safety outcome—grade 2 or higher cytokine release syndrome—and was reported in 12 participants, but the uncontrolled design provides limited evidence of treatment effectiveness.
Next expected readout: December 2026 · NCT06421675 (registry estimate)
GR1803
Developed by Genrix Bio
NCT07102706 · Phase 1/2 · completed
The study assigned participants sequentially to different GR1803 doses without randomization, blinding, or a control group. Its primary endpoint was dose-limiting toxicity over 52 weeks, but the registry does not report whether this endpoint was met.
Next expected readout: May 2027 · NCT06566547 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elranatamab's landscape · GR1803's landscape